VIVORYON THERAPEUTICS N.V. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.928 EUR | -2.33% |
|
+38.31% | -76.31% |
| Jun. 24 | Vivoryon Therapeutics N.V.(ENXTAM:VVY) dropped from Netherlands ASCX AMS Small Cap Index | CI |
| Jun. 24 | Vivoryon Therapeutics N.V.(ENXTAM:VVY) dropped from S&P Global BMI Index | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 51.46M 55.26M |
|---|---|---|---|---|---|
| Net income 2024 * | -23M -24.7M | Net income 2025 * | -16M -17.18M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 19.94M 21.42M | Net cash position 2025 * | 5.54M 5.95M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.24
x | P/E ratio 2025 * |
-3.24
x | Employees | 15 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vivoryon Therapeutics N.V.
More press releases
| 1 day | +2.81% | ||
| 1 week | +11.40% | ||
| Current month | +6.70% | ||
| 1 month | -17.58% | ||
| 3 months | +276.72% | ||
| 6 months | -75.72% | ||
| Current year | -75.75% |
1 week
1.32
2.36
1 month
1.323.06
Current year
0.419.93
1 year
0.4114.10
3 years
0.4123.25
5 years
0.4123.25
10 years
0.4127.73
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Director/Board Member | 56 | 18-08-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 06-12-31 | |
| Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 1.928 | -2.33% | 123 032 |
| 24-07-02 | 1.974 | +2.81% | 143,991 |
| 24-07-01 | 1.92 | +3.78% | 350,513 |
| 24-06-28 | 1.85 | -3.95% | 1,622,300 |
| 24-06-27 | 1.926 | +38.16% | 1,650,370 |
Real-time Euronext Amsterdam, July 02, 2024 at 11:35 am EDT
More quotes
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2023, the group has a portfolio of a product in phase II-B clinical development (Varoglutamstat; PQ912).
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.974
EUR
Average target price
41.57
EUR
Spread / Average Target
+2,005.71%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -75.75% | 55.25M | |
| +17.72% | 44.87B | |
| -10.33% | 37.8B | |
| +37.55% | 37.61B | |
| +29.36% | 31.32B | |
| -8.44% | 27.4B | |
| +12.45% | 26.32B | |
| +44.19% | 14.07B | |
| +31.93% | 12.5B | |
| -7.67% | 11.23B |
- Stock Market
- Equities
- VVY Stock
